探讨安罗替尼治疗晚期非小细胞肺癌的临床效果与安全性  

Discussion on the clinical effect and safety of anlotinib in the treatment of advanced non-small cell lung cancer

作　　者：邱伊连 黄萍 刘萍 谢传华 郭守俊 QIU Yi-lian;HUANG Ping;LIU Ping(First Department of Internal Medicine,Ganzhou Cancer Hospital,Ganzhou 341000,China)

机构地区：[1]赣州市肿瘤医院内科一区,341000

出　　处：《中国实用医药》2023年第19期25-29,共5页China Practical Medicine

摘　　要：目的探讨安罗替尼治疗晚期非小细胞肺癌(NSCLC)的临床效果与安全性。方法80例晚期NSCLC患者,随机分为对照组与观察组,每组40例。对照组实施吉西他滨联合顺铂治疗,观察组在对照组基础上联合安罗替尼治疗。比较两组患者的临床治疗效果、生活质量、负性情绪、肺功能、肿瘤相关因子水平及不良反应发生率。结果观察组治疗总有效率95.00%高于对照组的70.00%,差异有统计学意义(P<0.05)。观察组生理职能、社会功能、躯体疼痛、一般健康状况评分分别为(75.23±3.45)、(83.25±3.45)、(90.24±4.57)、(94.25±5.53)分,高于对照组的(66.56±2.63)、(72.46±3.64)、(76.54±4.35)、(83.64±4.75)分,差异有统计学意义(P<0.05)。治疗后,观察组焦虑自评量表(SAS)和抑郁自评量表(SDS)评分分别为(26.25±2.48)、(22.18±2.48)分,低于对照组的(39.58±3.18)、(36.58±3.58)分,差异有统计学意义(P<0.05)。观察组第1秒用力呼气容积与用力肺活量比值(FEV1/FVC)、呼气峰值流速(PEF)、第1秒用力呼气容积占预计值的百分比(FEV1%)分别为(69.26±11.34)%、(320.65±52.66)L/min、(70.65±16.66)%,高于对照组的(62.65±13.33)%、(260.64±81.76)L/min、(62.53±11.65)%,差异有统计学意义(P<0.05)。观察组肿瘤坏死因子-β_(1)、血管内皮生长因子、基质金属蛋白酶2、组织金属蛋白酶抑制剂水平低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率2.50%低于对照组的25.00%,差异有统计学意义(P<0.05)。结论安罗替尼治疗晚期NSCLC效果显著,可有效改善患者生活质量、负情绪、肺功能及肿瘤相关因子,且安全性较高,值得推广。Objective To discuss the clinical effect and safety of anlotinib in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 80 patients with advanced NSCLC were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with gemcitabine and cisplatin,and the observation group was treated with anlotinib on the basis of the control group.The clinical therapeutic effect,quality of life,negative emotion,lung function,tumor-related factors,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.00%,which was higher than that of 70.00%of the control group,and the difference was statistically significant(P<0.05).The scores of role physical,social functioning,bodily pain and general health status in the observation group were(75.23±3.45),(83.25±3.45),(90.24±4.57)and(94.25±5.53)points,which were higher than those of(66.56±2.63),(72.46±3.64),(76.54±4.35)and(83.64±4.75)points in the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of self-rating anxiety scale(SAS)and self-rating depression scale(SDS)in the observation group were(26.25±2.48)and(22.18±2.48)points,which were lower than those of(39.58±3.18)and(36.58±3.58)points in the control group,and the differences were statistically significant(P<0.05).The ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC),peak expiratory flow rate(PEF),and forced expiratory volume in one second as a percentage of the predicted value(FEV1%)in the observation group were(69.26±11.34)%,(320.65±52.66)L/min,and(70.65±16.66)%,which were higher than those of(62.65±13.33)%,(260.64±81.76)L/min,and(62.53±11.65)%in the control group,and the differences were statistically significant(P<0.05).The levels of tumor necrosis fact-β_(1),vascular endothelial growth factor,matrix metalloproteinase 2 and tissue metalloproteinase inhibitor in the observa

关 键 词：安罗替尼 晚期非小细胞肺癌 吉西他滨 顺铂 肺功能 肿瘤相关因子 

分 类 号：R734.2[医药卫生—肿瘤]